IDH2 and glioblastoma: More than 70% of the WHO grade II and III astrocytomas, oligodendrogliomas, and glioblastomas originating from these low-grade lesions have mutations affecting amino acid 132 of IDH1, and alterations affecting IDH2-like amino acids R172 are common in tumors without IDH1 mutations (6).